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Dear editor
We read the article titled “Internal mammary sentinel lymph node biopsy: abandon 
or persist?” by Qiu et al with high interest. This was an excellent paper regarding the 
contemporary management of internal mammary lymph nodes (IMLN) in early-stage 
breast cancer1 and we would like to take this opportunity to comment on this paper.
There are several unresolved questions regarding early-stage breast manage-
ment including axillary staging, clear resection margin, or IMLN.2–4 We have been 
focusing on the issues of IMLN for almost a decade and just recently published our 
data regarding IMLN management. We absolutely agree that one has to carefully 
balance the benefit and potential risks of biopsy or radiotherapy of IMLN. Our 
current practice is not to do biopsy/not to irradiate IMLN unless they are clinically 
enlarged. However, we are always cautious about the visualization of sentinel 
lymph nodes by sentinel lymph node biopsy (SLNB) in internal mammary chain. 
We reviewed all breast cancer patients who underwent SLNB in our department 
from 2008 to 2012 to achieve 5 years median follow-up and to figure out whether 
IMLN drainage acts as a negative prognostic factor in case if they are left without 
any management. Our trial included more than 700 patients and the results obtained 
concluded no detrimental effect of IMLN drainage during SLNB procedure. There 
was no statistically significant difference in overall survival and local or distant 
recurrence rate.5 Our findings are in contrast to that of other trials6 recommending 
radiotherapy for IMLN; even trials such as MA.20 or EORTC 22922 that focused 
on axillary lymph node radiotherapy have recommended radiotherapy for IMLN. 
However, we believe that the difference observed might be due to the difference 
in the enrollment period. Our trial enrolled patients in the era of targeted therapy, 
taxanes, and dose-dense chemotherapy as a standard for breast cancer patients. 
These chemotherapy regimens may potentially compensate for uncertainties in the 
local management of IMLN. We believe these results are in line with the gener-
ally accepted contemporary trend toward less-radical locoregional treatment of 
the early-stage breast cancer, and further trials have to be carried out to confirm 
our findings.
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Dear editor
We appreciate the letter from Professors Vrana and Gatek 
regarding our article titled “Internal mammary sentinel lymph 
node biopsy: abandon or persist?”.1 We have been following 
their publications regarding internal mammary lymph nodes 
(IMLN) management since the publication of their article 
titled “Prognostic influence of internal mammary node drain-
age in patients with early-stage breast cancer” in December 
20162 and we share their interest on this topic.
Their trials retrospectively reviewed patients with breast 
cancer who underwent sentinel lymph node biopsy (SLNB), 
and IMLN drainage was assessed as a potential risk factor 
for local and distant disease recurrences. We agree that the 
drainage of IMLN is unlikely to have a detrimental effect 
on patient outcome. However, their results did not mean that 
IMLN does not need any management, because presence of 
IMLN drainage should not be interpreted as having IMLN 
metastasis and absence of IMLN drainage as not having 
IMLN metastasis. We believe that the assessment of prognos-
tic influence should be based on IMLN metastasis rather than 
only on IMLN drainage. Moreover, their study population 
had been limited to the clinically axilla lymph node (ALN)-
negative patients, and the incidence of IMLN metastasis in 
these patients is only about 10% as reported.3 Therefore, the 
difference was small even if there was a difference between 
the patients with and without IMLN drainage.
It was recognized that the benefit of systemic therapy 
on locoregional control had transformed the pattern of 
breast cancer therapy, and within the changing treatment 
approach – more systemic therapy, less locoregional 
therapy – clinicians should deliberate the application of 
regional IMLN therapy. The absolute benefit of internal mam-
mary radiotherapy (IMRT) has been decreased with the appli-
cations of effective systemic treatments, but it still exists.4 The 
2016 NCCN Guidelines recommend IMRT for patients with 
MLN therapy. The absolute be and strongly consider IMRT 
for patients with 1–3 positive ALN (category 2A). Studies 
of extended radical mastectomy reported that 36.8%–46.2% 
patients with $4 positive ALN and 18.8%–26.7% patients 
with 1–3 positive ALN identified with IMLN metastases.5,6 
Therefore, IMRT should be tailored and balanced between 
the benefit and potential risks, and internal mammary sentinel 
lymph node biopsy (IM-SLNB) might be a minimally inva-
sive staging technique that guides the tailored IMRT. In our 
recent study, we tried injecting radiotracer with a modified 
technique (periareolar intraparenchymal, high volume and 
ultrasound guidance) and obtained a high IM-SLN detec-
tion rate of 75.1%. We found that the IM-SLN metastasis 
rate was only 8.1% in clinically ALN-negative patients 
whereas it was 20.5% in clinically ALN-positive patients, 
and individual IMRT strategy could be guided based on 
IM-SLNB results.7–10 We recommend that IM-SLNB should 
be performed in all clinically ALN-positive patients and 
selectively in high-risk (upper inner quadrant tumor and/or 
ALN-positive) clinically ALN-negative patients.
Finally, we encourage that IM-SLNB study should still be 
performed in breast cancer patients, especially for high-risk 
IMLN involvement, and prognostic assessment of IM-SLNB 
metastasis is essential in order to improve diagnosis and provide 
a more individual IMRT and a more accurate prognosis.
Disclosure
The authors report no conflicts of interest in this commu-
nication.
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